Document is current
Any future updates will be listed below
-
Authors
Ohyagi, Masaki https://orcid.org/0000-0002-6009-450X
Nagata, Tetsuya https://orcid.org/0000-0003-4111-2693
Ihara, Kensuke https://orcid.org/0000-0002-2436-9588
Yoshida-Tanaka, Kie
Nishi, Rieko https://orcid.org/0000-0003-2733-0053
Miyata, Haruka
Abe, Aya
Mabuchi, Yo https://orcid.org/0000-0001-8008-3966
Akazawa, Chihiro
Yokota, Takanori https://orcid.org/0000-0002-6490-3263
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (17H06109, 19H01016, 17H06109, 19H01016)
Japan Agency for Medical Research and Development (20am0401006h0002)
- License Information
-
More Information
Article History
Received: 28 March 2020
Accepted: 19 October 2021
First Online: 22 December 2021
Competing interests
: T.Y. collaborates with Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Rena Therapeutics Inc. and serves as an academic advisor for RENA Therapeutics Inc. and Braizon Therapeutics Inc. The other authors declare no competing interests.
